[Cis-diamminedichloroplatinum (CDDP)-radiation therapy in nasopharyngeal carcinoma]. 1986

M Chatani, and T Teshima, and T Inoue, and Y Tsuruta, and K Umatani, and K Yoshino, and H Miyahara, and T Sato

Between July 1977 and October 1983, 40 patients with nasopharyngeal carcinoma were treated by radiation therapy. From the investigation of this series, prophylactic treatment for distant metastases was recommended for good prognosis. Between November 1983 and May 1985, 10 patients with nasopharyngeal carcinoma were treated using a combination of cis-diamminedichloroplatinum (CDDP) and radiation therapy. Treatment results showed complete response in all 10 patients. One patient failed in the out field of boost therapy after whole-neck irradiation. This patient has shown no distant metastases. The remaining 9 patients have been controlled well. Major side effects were renal toxicity, and nausea and vomiting, which were mostly transient. However, severe mucositis of the oral cavity was observed in 4 patients (40%) of the CDDP-radiation group in contrast with 3 patients (8%) of the radiation-therapy-only group (p less than 0.01).

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009303 Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX. Cancer of Nasopharynx,Nasopharyngeal Cancer,Cancer of the Nasopharynx,Nasopharynx Cancer,Nasopharynx Neoplasms,Neoplasms, Nasopharyngeal,Cancer, Nasopharyngeal,Cancer, Nasopharynx,Cancers, Nasopharyngeal,Cancers, Nasopharynx,Nasopharyngeal Cancers,Nasopharyngeal Neoplasm,Nasopharynx Cancers,Nasopharynx Neoplasm,Neoplasm, Nasopharyngeal,Neoplasm, Nasopharynx,Neoplasms, Nasopharynx
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

M Chatani, and T Teshima, and T Inoue, and Y Tsuruta, and K Umatani, and K Yoshino, and H Miyahara, and T Sato
March 1988, International journal of radiation oncology, biology, physics,
M Chatani, and T Teshima, and T Inoue, and Y Tsuruta, and K Umatani, and K Yoshino, and H Miyahara, and T Sato
June 1984, Tumori,
M Chatani, and T Teshima, and T Inoue, and Y Tsuruta, and K Umatani, and K Yoshino, and H Miyahara, and T Sato
October 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
M Chatani, and T Teshima, and T Inoue, and Y Tsuruta, and K Umatani, and K Yoshino, and H Miyahara, and T Sato
January 1984, Cancer chemotherapy and pharmacology,
M Chatani, and T Teshima, and T Inoue, and Y Tsuruta, and K Umatani, and K Yoshino, and H Miyahara, and T Sato
April 1993, Journal of neuro-oncology,
M Chatani, and T Teshima, and T Inoue, and Y Tsuruta, and K Umatani, and K Yoshino, and H Miyahara, and T Sato
February 1984, Clinical biochemistry,
M Chatani, and T Teshima, and T Inoue, and Y Tsuruta, and K Umatani, and K Yoshino, and H Miyahara, and T Sato
November 1990, Nihon Gan Chiryo Gakkai shi,
M Chatani, and T Teshima, and T Inoue, and Y Tsuruta, and K Umatani, and K Yoshino, and H Miyahara, and T Sato
January 1986, Cancer chemotherapy and pharmacology,
M Chatani, and T Teshima, and T Inoue, and Y Tsuruta, and K Umatani, and K Yoshino, and H Miyahara, and T Sato
April 1985, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
M Chatani, and T Teshima, and T Inoue, and Y Tsuruta, and K Umatani, and K Yoshino, and H Miyahara, and T Sato
August 1988, Nihon Gan Chiryo Gakkai shi,
Copied contents to your clipboard!